MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Harvard Bioscience Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.66 3.13

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.65

Max

0.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1M

-1.2M

Pardavimai

141K

21M

Pelno marža

-5.978

Darbuotojai

330

EBITDA

1M

1.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+198.51% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4M

30M

Ankstesnė atidarymo kaina

-2.47

Ankstesnė uždarymo kaina

0.66

Naujienos nuotaikos

By Acuity

50%

50%

157 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Harvard Bioscience Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-31 22:20; UTC

Pagrindinės rinkos jėgos

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025-12-31 17:31; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025-12-31 16:30; UTC

Pagrindinės rinkos jėgos

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025-12-31 15:19; UTC

Pagrindinės rinkos jėgos

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025-12-31 15:17; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025-12-31 14:37; UTC

Pagrindinės rinkos jėgos

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2025-12-31 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:13; UTC

Įsigijimai, susijungimai, perėmimai

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025-12-31 20:40; UTC

Rinkos pokalbiai

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025-12-31 20:22; UTC

Rinkos pokalbiai

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025-12-31 19:50; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025-12-31 19:31; UTC

Rinkos pokalbiai

Precious Metals Cap Off Record Runs -- Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025-12-31 17:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025-12-31 17:16; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025-12-31 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-31 17:00; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025-12-31 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025-12-31 15:54; UTC

Rinkos pokalbiai

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025-12-31 15:02; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025-12-31 14:40; UTC

Įsigijimai, susijungimai, perėmimai

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025-12-31 14:20; UTC

Rinkos pokalbiai

Crude Futures On Track to End the Year With Losses -- Market Talk

2025-12-31 13:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

2025-12-31 13:01; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

2025-12-31 11:10; UTC

Rinkos pokalbiai

Copper Remains in Touching Distance of Record Highs -- Market Talk

2025-12-31 10:46; UTC

Rinkos pokalbiai

Euro on Track For Strong Annual Performance -- Market Talk

2025-12-31 10:25; UTC

Rinkos pokalbiai

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

2025-12-31 10:23; UTC

Rinkos pokalbiai

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

2025-12-31 09:33; UTC

Rinkos pokalbiai

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harvard Bioscience Inc Prognozė

Kainos tikslas

By TipRanks

198.51% į viršų

12 mėnesių prognozė

Vidutinis 2 USD  198.51%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harvard Bioscience Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.3 / 0.3401Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

157 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat